A Study Of PF-06263507 In Patients With Advanced Solid Tumors

Pfizer

Status and phase: Terminated; Phase 1

Conditions: Carcinoma, Non Small Cell Lung; Ovarian Neoplasms; Neoplasms; Breast Neoplasms

Treatments: Drug: PF-06263507

Study type: Interventional

Funder types: Industry

Identifiers

NCT01891669

B4481001

Details and patient eligibility

About

To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Enrollment: 26 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for which no standard therapy is available.
• Performance Status of 0 or 1.
• Adequate bone marrow, kidney, liver, and heart function.

Exclusion criteria

• Brain metastases requiring steroids.
• Major surgery or anti-cancer therapy within 4 weeks of study treatment start.
• Active bacterial, fungal or viral infection.

Trial design

26 participants in 1 patient group

Part 1

Experimental group

Treatment:

Drug: PF-06263507

Drug: PF-06263507